Stemline Therapeutics gets FDA green light for ElzonrisThe Food and Drug Administration has approved the first treatment for BPDCN, a rare blood disease. Shire gets FDA’s blessing for MotegrityShire plans to launch Motegrity for chronic idiopathic constipation in 2019. Glenmark to make foray into branded dermatology segment Glenmark enters branded dermatology segment in the U.S., which had a market value of roughly $1.9 billion. Alexion Pharmaceuticals gets FDA nod for Ultomiris Alexion's Ultomiris is a new treatment for adult patients with PNH, a rare, life-threatening blood disease. Servier gets FDA clearance for Asparlas Servier's Asparlas provides for a longer interval between doses versus other pegaspargase products. AstraZeneca, Merck's Lynparza is approved by FDA Lynparza is the first PARP inhibitor approved for first-line maintenance in BRCAm advanced ovarian cancer. Astellas launches Xospata Astellas Pharma is introducing Xospata, an oral monotherapy for patients with acute myeloid leukemia. Mayne Pharma gets FDA nod for Tolsura Mayne Pharma's Tolsura provides a new formulation of itraconazole for fungal infections. FDA approves Catalyst’s Firdapse Catalyst's Firdapse provides a treatment for Lambert-Eaton myasthenic syndrome — a rare autoimmune disorder. Astellas gets FDA green light for Xospata Xospata's approval marks the first FLT3-targeting therapy for acute myeloid leukemia. First Previous 43 44 45 46 47 Next Last
